NO20065613L - 3-karbamoyl-2-pyridonderivat. - Google Patents

3-karbamoyl-2-pyridonderivat.

Info

Publication number
NO20065613L
NO20065613L NO20065613A NO20065613A NO20065613L NO 20065613 L NO20065613 L NO 20065613L NO 20065613 A NO20065613 A NO 20065613A NO 20065613 A NO20065613 A NO 20065613A NO 20065613 L NO20065613 L NO 20065613L
Authority
NO
Norway
Prior art keywords
hydrogen
alkyl
optionally substituted
itch
compounds
Prior art date
Application number
NO20065613A
Other languages
English (en)
Norwegian (no)
Inventor
Natsuki Ishizuka
Takashi Sasatani
Yoshilharu Hiramatsu
Masanao Inagaki
Masahide Odan
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of NO20065613L publication Critical patent/NO20065613L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
NO20065613A 2004-10-28 2006-12-06 3-karbamoyl-2-pyridonderivat. NO20065613L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004313947 2004-10-28
JP2005159995 2005-05-31
PCT/JP2005/020248 WO2006046778A1 (ja) 2004-10-28 2005-10-28 ３－カルバモイル－２－ピリドン誘導体

Publications (1)

Publication Number Publication Date
NO20065613L true NO20065613L (no) 2007-05-29

Family

ID=36227998

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065613A NO20065613L (no) 2004-10-28 2006-12-06 3-karbamoyl-2-pyridonderivat.

Country Status (17)

Country Link
US (2) US8178681B2 (ru)
EP (1) EP1806342B1 (ru)
JP (4) JP4234176B2 (ru)
KR (2) KR100902798B1 (ru)
CN (1) CN1993327B (ru)
AU (2) AU2005297799B2 (ru)
BR (1) BRPI0512985A (ru)
CA (1) CA2572208C (ru)
ES (1) ES2421143T3 (ru)
IL (1) IL180331A (ru)
IS (1) IS8578A (ru)
MX (1) MX2007001320A (ru)
NO (1) NO20065613L (ru)
NZ (1) NZ551936A (ru)
RU (1) RU2392271C2 (ru)
TW (2) TWI360539B (ru)
WO (1) WO2006046778A1 (ru)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977266B2 (en) * 2000-12-28 2005-12-20 Shionogi & Co., Ltd. Pyridone derivatives having affinity for cannabinoid 2-type receptor
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
TWI360539B (en) * 2004-10-28 2012-03-21 Shionogi & Co 3-carbamoyl-2-pyridone derivatives
KR20080023680A (ko) 2005-05-10 2008-03-14 인터뮨, 인크. 스트레스-활성화 단백질 키나제 시스템을 조절하기 위한피리돈 유도체
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
TW200812963A (en) * 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
US8791264B2 (en) * 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
ES2431466T3 (es) * 2006-06-30 2013-11-26 Sunesis Pharmaceuticals, Inc. Inhibidores de piridinonil pdk1
CN101511796B (zh) 2006-09-05 2012-05-09 协和发酵麒麟株式会社 咪唑衍生物
EP2070927A4 (en) * 2006-09-13 2010-10-13 Kyowa Hakko Kirin Co Ltd CONDENSED HETEROCYCLIC DERIVATIVE
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
WO2008084671A1 (ja) * 2006-12-27 2008-07-17 Shionogi & Co., Ltd. １－置換－２－ピリドン－３－カルボン酸誘導体の製造方法
WO2008109991A1 (en) * 2007-03-09 2008-09-18 University Health Network Inhibitors of carnitine palmitoyltransferase and treating cancer
WO2008124118A1 (en) * 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
WO2009015485A1 (en) * 2007-08-01 2009-02-05 University Health Network Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer
WO2009040659A2 (en) * 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US8466284B2 (en) * 2007-11-06 2013-06-18 Astra Zeneca Ab Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
BRPI0820162A2 (pt) * 2007-11-20 2019-09-24 Merck Sharp & Dohme composto, composição farmacêutica, método para a profilazia ou tratamento de infecção pela hiv ou para a profilaxia, tratamento ou retardo no início da aids
CN101215261B (zh) * 2008-01-03 2011-09-07 南京大学 合成2-氧代-3-吡啶甲酸酯及其衍生物的方法
MX2010012848A (es) 2008-06-03 2011-03-01 Intermune Inc Compuestos y metodos para tratar trastornos inflamatorios y fibroticos.
US20110098324A1 (en) * 2008-06-25 2011-04-28 Brackley Iii James A Prolyl hydroxylase inhibitors
KR20110028661A (ko) * 2008-07-15 2011-03-21 노파르티스 아게 Ｄｇａｔ１ 억제제로서의 헤테로아릴 유도체
US20110144167A1 (en) * 2008-08-25 2011-06-16 Smithkline Beecham Corporation Prolyl Hydroxylase Inhibitors
TW201036957A (en) * 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
CA2760151A1 (en) * 2009-04-27 2010-11-04 Elan Pharmaceuticals, Inc. Pyridinone antagonists of alpha-4 integrins
US8299103B2 (en) * 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
EP2459182B1 (en) 2009-07-30 2017-09-06 University of Zürich Injectable formulation for treatment and protection of patients having an inflammatory reaction or an ischemia-reperfusion event
JP5748947B2 (ja) * 2009-09-01 2015-07-15 公益財団法人相模中央化学研究所 ２−アシルアミノチアゾール誘導体及びその製造方法
CN103492367B (zh) * 2011-02-17 2015-04-01 拜耳知识产权有限责任公司 用于治疗的取代的3-(联苯-3-基)-8,8-二氟-4-羟基-1-氮杂螺[4.5]癸-3-烯-2-酮
MX2014002297A (es) * 2011-08-29 2014-07-22 Ptc Therapeutics Inc Compuestos antibacterianos y metodos para su uso.
US9409905B2 (en) 2011-08-29 2016-08-09 Ptc Therapeutics, Inc. Antibacterial compounds and methods for use
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CN106459042B (zh) 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
WO2016045128A1 (en) * 2014-09-28 2016-03-31 Merck Sharp & Dohme Corp. Inhibitors of hif prolyl hydroxylase
WO2016045126A1 (en) * 2014-09-28 2016-03-31 Merck Sharp & Dohme Corp. Inhibitors of hif prolyl hydroxylase
WO2016045125A1 (en) * 2014-09-28 2016-03-31 Merck Sharp & Dohme Corp. Inhibitors of hif prolyl hydroxylase
CA3021660A1 (en) 2016-04-22 2017-10-26 Receptor Life Sciences, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
KR102253487B1 (ko) * 2017-01-03 2021-05-18 삼성전자주식회사 전선커버유닛을 포함하는 빌트인 냉장고

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010021696A (ko) 1997-07-11 2001-03-15 미즈노 마사루 퀴놀린 화합물 및 그의 의약용도
JP2000256323A (ja) * 1999-01-08 2000-09-19 Japan Tobacco Inc ２−オキソキノリン化合物及びその医薬用途
WO2000066104A2 (en) 1999-04-30 2000-11-09 Millennium Pharmaceuticals, Inc. Ace-2 inhibiting compounds and methods of use thereof
CA2386474A1 (en) 1999-09-20 2001-03-29 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
JP4982937B2 (ja) 2000-08-01 2012-07-25 小野薬品工業株式会社 ３，４−ジヒドロイソキノリン誘導体化合物及びその化合物を有効成分とする薬剤
US7420030B2 (en) * 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
WO2002039997A2 (en) 2000-11-01 2002-05-23 Millennium Pharmaceuticals, Inc. Ace-2 modulating compounds and use thereof
US6977266B2 (en) * 2000-12-28 2005-12-20 Shionogi & Co., Ltd. Pyridone derivatives having affinity for cannabinoid 2-type receptor
GB0104268D0 (en) 2001-02-21 2001-04-11 Unilever Plc Antiperspirant or deodorant compositions
ATE406867T1 (de) 2001-07-18 2008-09-15 Unilever Nv Zusammensetzungen für die behandlung von haaren und/oder kopfhaut
TWI250023B (en) 2001-10-22 2006-03-01 Santen Pharmaceutical Co Ltd Pharmaceutical composition for itch treating agent
US20040259936A1 (en) 2001-12-07 2004-12-23 Nagarkatti Leonard C Treatment of neoplasia
WO2003061699A1 (fr) 2001-12-27 2003-07-31 Japan Tobacco, Inc. Remedes pour affections allergiques
US20050101590A1 (en) 2002-02-19 2005-05-12 Kiyoshi Yasui Antipruritics
WO2004103974A1 (ja) 2003-05-23 2004-12-02 Japan Tobacco Inc. 置換２－オキソキノリン化合物およびその医薬用途
WO2004104000A1 (ja) 2003-05-23 2004-12-02 Japan Tobacco Inc. トリサイクリック縮合環化合物およびその医薬用途
JP2007501844A (ja) 2003-08-08 2007-02-01 トランス　テック　ファーマ，インコーポレイテッド アリール及びヘテロアリール化合物、組成物並びに使用方法
US7732442B2 (en) 2003-09-05 2010-06-08 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonist and medical use thereof
GB0402355D0 (en) 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
WO2005099688A2 (en) 2004-04-07 2005-10-27 Takeda Pharmaceutical Company Limited Cyclic compounds
TWI360539B (en) * 2004-10-28 2012-03-21 Shionogi & Co 3-carbamoyl-2-pyridone derivatives

Also Published As

Publication number Publication date
JP2008179635A (ja) 2008-08-07
CA2572208C (en) 2011-08-09
CA2572208A1 (en) 2006-05-04
JP4998952B2 (ja) 2012-08-15
KR100902798B1 (ko) 2009-06-12
EP1806342B1 (en) 2013-04-17
EP1806342A1 (en) 2007-07-11
US8178681B2 (en) 2012-05-15
IL180331A (en) 2011-12-29
RU2392271C2 (ru) 2010-06-20
MX2007001320A (es) 2007-04-02
RU2006147307A (ru) 2008-07-10
JP4234183B2 (ja) 2009-03-04
JP4234176B2 (ja) 2009-03-04
TW200843761A (en) 2008-11-16
AU2009202373B2 (en) 2011-01-06
TW200619199A (en) 2006-06-16
US20080103139A1 (en) 2008-05-01
WO2006046778A1 (ja) 2006-05-04
KR20070046944A (ko) 2007-05-03
JP4234184B2 (ja) 2009-03-04
KR20080070878A (ko) 2008-07-31
IL180331A0 (en) 2007-07-04
JP2008156366A (ja) 2008-07-10
BRPI0512985A (pt) 2008-04-22
IS8578A (is) 2006-12-08
US8367666B2 (en) 2013-02-05
ES2421143T3 (es) 2013-08-29
CN1993327B (zh) 2013-02-06
AU2009202373A1 (en) 2009-07-02
CN1993327A (zh) 2007-07-04
AU2005297799B2 (en) 2009-04-09
NZ551936A (en) 2010-07-30
JPWO2006046778A1 (ja) 2008-05-22
EP1806342A4 (en) 2010-02-17
US20120208813A1 (en) 2012-08-16
TWI360539B (en) 2012-03-21
JP2008156365A (ja) 2008-07-10
AU2005297799A1 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
NO20065613L (no) 3-karbamoyl-2-pyridonderivat.
EA200601830A1 (ru) Ортозамещённые арильные или гетероарильные амидные соединения
BRPI0707491B8 (pt) compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
EA201101089A1 (ru) Производные оксадиазола в качестве агонистов рецептора s1p1
NO20073325L (no) Nye naftalenforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
WO2005080384A3 (en) Benzimidazole derivative and use as aii receptor antagonist
NO20065578L (no) Substituerte metylaryl eller heteroarylamidforbindelser
BRPI0612926B8 (pt) compostos fluorados de 4-(2-amino-1-hidroxietila)fenol como agonistas de receptores b2 adrenérgicos, composição farmacêutica, combinação e uso de um composto
RS52519B (en) SPIROCYCLIC COMPOUNDS WHICH ARE INHIBITORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
NO20055688L (no) Organiske forbindelser
WO2008101935A3 (fr) Nouveaux composés dérivés d'indole et compositions pharmaceutiques les contenant
UY30387A1 (es) Nuevos compuestos
ATE552246T1 (de) Substituierte aryloxy-n- bicyclomethylacetamidverbindungen als vr1- antagonisten
MX2010001576A (es) Compuestos 3´sustituidos que tienen afinidad con el receptor 5-hidroxitriptamina 6 (5-ht6).
NO20072409L (no) Substituerte n-sulfonylaminobenzyl-2-fenoksy acetamid-forbindelser
NO20071314L (no) Peptidiske vasopressinreseptoragonister
ME00680B (me) Nova jedinjenja diozmetina, postupak za njihovo dobijanje i farmaceutske kompozicije koje ih sadrže
MA33675B1 (fr) Composé indazole et pyrazolopyridine en tant qu'antagonistes du récepteur ccr1
MX2009008324A (es) Compuestos 6´-sustituidos que tienen afinidad con el receptor de 5-hidroxitriptamina-6.
NO20075618L (no) Novel compounds as GLP-1 Agonists
MY165634A (en) Pyrazole compounds having therapeutic effect on multiple myeloma
EA201390374A1 (ru) Гетероциклические соединения для лечения или профилактики расстройств, вызываемых ослабленной нейротрансмиссией серотонина, норэпинефрина или допамина
DE602005014629D1 (de) Pyrazolphenylderivate als ppar-aktivatoren
ATE465151T1 (de) 4-aryloxy-chinolin-derivate als 5-ht6-modulatoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application